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http://dx.doi.org/10.1016/j.stemcr.2016.04.010SUMMARYDefining the molecular regulators of hematopoietic stem and progenitor cells (HSPCs) requires in vivo functional analyses. Competitive
bone marrow transplants (BMTs) compare control and test HSPCs to demonstrate the functional role of a genetic change or chemical
perturbation. Competitive BMT is enabled by antibodies that specifically recognize hematopoietic cells from congenic mouse strains
due to variants of the cell surface protein CD45, designated CD45.1 and CD45.2. The current congenic competitor strain, B6.SJL-Ptprca
Pepcb/BoyJ (CD45.1), has a substantial inherent disadvantage in competition against the C57BL/6 (CD45.2) strain, confounding exper-
imental interpretation. Despite backcrossing, the congenic interval over which the B6.SJL-Ptprca Pepcb/BoyJ strain differs is almost 40Mb
encoding 300 genes. Here, we demonstrate that a single amino acid change determines the CD45.1 epitope. Further, we report on the
single targeted exon mutant (STEM) mouse strain, CD45.1STEM, which is functionally equivalent to CD45.2 cells in competitive BMT.
This strain will permit the precise definition of functional roles for candidate genes using in vivo HSPC assays.INTRODUCTION
The development of transgenic and knockout mouse
models has permitted an examination of how the gain of
or loss of a particular gene affects the fitness of hematopoi-
etic stem and progenitor cells (HSPCs). One commonly
used approach is to transplant recipientmice with an equal
combination of normal and genetically modified HSPCs.
By following the progeny of the transplanted cells in the
recipient mice over the course ofR16 weeks, one can iden-
tify genetic modifications that give the HSPC a functional
advantage or disadvantage compared with wild-type (WT)
cells. This competitive transplant approach is a critical
tool for assessing the in vivo functional impact of genetic
(knockout, transgenic, knockin) or chemical modifica-
tions, and has been extremely useful in advancing HSPC
biology (Figure 1A).
In the competitive transplantation model, a means of
distinguishing normal and genetically modified stem cells
is essential. Fluorescent protein tagging is theoretically
attractive, but the efficiency of labeling, effects of the fluo-
rophore expression on cell function, and immunogenicity
of the non-native protein are limitations that compromise
its utility. The most commonly used approach of in vivo
tracking takes advantage of polymorphisms in the extracel-
lular domain of the transmembrane receptor tyrosine
phosphatase protein CD45 (Ly5, Ptprc, B220), a 220-kDa
protein expressed on all subsets of leukocytes.
The CD45.1 and CD45.2 alleles differ by only five
amino acids within the extracellular domain (ZebedeeStem
This is an open access article under the Cet al., 1991), resulting in epitope changes that permit
specific recognition by monoclonal antibodies (Shen,
1981). The majority of the commonly used mouse strains
express the CD45.2 allele. Backcrossing of mice expressing
the CD45.1 allele (SJL) into the C57BL/6 background
(CD45.2) has resulted in the development of the mouse
strain B6.SJL-PtprcaPepcb/Boy (B6.SJL). As the mice have
been backcrossed over many generations, they have been
termed congenic, with the presumption that they differ
only at the CD45 locus. Table 1 contains a description of
the nomenclature for the mouse strains described in this
article.
A competitive transplant is typically performed by trans-
planting an equal number of CD45.1 and CD45.2 donor
cells into the background of CD45.1, CD45.2, or heterozy-
gous (CD45.1/2) mice. As the recipient mice are given a
myeloablative dose of g-irradiation prior to the transplant,
there are few (usually less than 5%, mostly T lymphocytes)
residual host cells, and thus the more-readily available and
less expensive CD45.2mice are generally used as transplant
recipients (Figure 1A). The advantage of using F1 CD45.1/2
heterozygote recipient mice is that the host residual cells
are doubly stained by both CD45.1 and CD45.2 mono-
clonal antibodies, and thus can be distinguished from the
transplanted cells.
Hundreds of competitive transplants have been re-
ported in the literature. Most of these are performed to
test the impact of a genetically modified test gene. Unfor-
tunately, the WT congenic B6.SJL (CD45.1) HSPCs have
an inherent disadvantage over WT C57BL/6 (CD45.2)Cell Reports j Vol. 6 j 985–992 j June 14, 2016 j ª 2016 The Authors 985
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A B Figure 1. The Current B6.SJL Strain Shows
an Inherent Competitive Disadvantage
(A) A model of a typical competitive bone
marrow transplantation experiment. In
the experiment, bone marrow cells from a
TEST (CD45.2) mouse are combined with an
equal number of bone marrow cells from a
COMPETITOR (CD45.1) mouse and trans-
planted into irradiated recipient mice. The
peripheral blood chimerism is followed for
16–20 weeks as a functional assay of he-
matopoietic stem cell fitness.
(B) HSPCs derived from the current B6.SJL
(CD45.1) competitor strain show an inherent
competitive disadvantage when compared
with HSPCs from wild-type C57BL/6 mice. In
these experiments, the bone marrow from
three littermate C57BL/6 mice or three littermate B6.SJL mice were pooled. 500,000 nucleated bone marrow cells from each donor strain
were combined (1 million cells total) and transplanted by intravenous injection in lethally irradiated recipients. Four experiments were
performed, two in competition with WT C57BL/6J donors and two in competition with WT C57BL/6NJ donors. Results represent the mean ±
SEM. Given the large number of replicates (74 recipient mice in each arm), the error bars are not visible as they are smaller than the squares.
***p < 0.001.HSPCs, with reported defects in homing efficiency, reduc-
tion in transplantable long-term hematopoietic stem cells,
and a cell-intrinsic engraftment defect as demonstrated by
Waterstrat et al. (2010) and us (Figure 1B). This advantage
is particularly marked if C57BL/6J mice are used as recip-
ients and is mildly attenuated when B6.SJL mice are used
as recipients, suggesting that B6.SJL cells may be impaired
in their ability to interact with C57BL/6J stromal cells
(Waterstrat et al., 2010). This lack of competitive balance
between the two putatively congenic strains has called
into question the interpretation of prior results con-
cerning the impact of modified genes and has created a
conundrum for the field.
In order to verify that changes in HSPC function are due
to the modified gene and not to the inherent imbalance of
the strains currently used in competitive transplantation,
an additional set of control experiments is required. To
compensate for the baseline engraftment defect of the
B6.SJL, which varies according to the experimental proto-
col (e.g., number of cells transplanted, conditioning
regimen, and strain of recipient), a competitive transplant
usingWTmicemust be performed in parallel. This requires
essentially double the number of mice and is not consis-
tently performed, resulting in ambiguity as to whether it
is the modified gene or the mouse strain that accounts for
differential engraftment.
The molecular basis for the inherent advantage of
C57BL/6J (CD45.2) HSPCs over B6.SJL (CD45.1) is not
known. The CD45 gene is inherited within a locus that
comprises almost 40 megabases and more than 300 pre-
dicted genes (Waterstrat et al., 2010). The basis for the
discordant HSPC function of the two genotypes is presum-986 Stem Cell Reports j Vol. 6 j 985–992 j June 14, 2016ably within this 40 Mb region and may include immuno-
logically or functionally active gene products.
Several international consortia, including KOMP
(Knock-Out Mouse Program) and EUCOMM (European
Conditional Mouse Mutagenesis Program), have ongoing
programs to generate new strains in the uniform C57BL/
6N background (Sacca et al., 2013). Thus, the ideal control
for HSPC characterization of these new strains is a func-
tionally equivalent C57BL/6N mouse with the minimal
change in the CD45 gene to render it detectable by a
CD45.1 antibody. Here, we define the specific epitope
difference between the CD45.1 and CD45.2 alleles and
describe the creation and testing of a CD45.1 knockin
point mutation in the background of the most commonly
used C57BL/6N mouse strain. Our data demonstrate
that, contrary to the B6.SJL strain, HSPC derived from
this mouse are functionally equivalent. We therefore pro-
pose that this mouse represents the ideal competitor for
competitive HSPC transplant, reducing the number of
controls required when working in the C57BL/6N back-
ground; we have named it CD45.1STEM (single targeted
exon mutation).RESULTS
A Single Amino Acid Change Confers the Differential
Recognition of CD45.1 and C45.2 Antibodies
The CD45 open reading frame (Gene 19,264, NM_
001111316) is 3,882 base pairs in length and encodes
a 1,293 amino acid protein (NP_001104786). This tran-
script comprises at least 33 exons (possibly up to 35 exons









CD45.2 The C57BL/6 syngeneic mouse has been bred for many generations at Jackson
Laboratory (J) and at the NIH (N), leading to subtle strain differences. The NIH
N substrain is also bred at Jackson Laboratory resulting in the NJ designation.
The N substrain is used in the International Mouse Knockout Program to generate





CD45.1 This is the currently used congenic strain. Despite backcrossing, the SJL mouse
differs from the C57BL/6 mouse by 40 Mb and 300 genes
C57BL/6N-CD45.1STEM 45.1STEM CD45.1 A single base/single amino acid change in the background of the C57BL/6N strain
results in the CD45.1STEM strainwith a number of variant transcripts) and the regulatory
importance of the corresponding introns is not known
(Holmes, 2006). The extracellular domain itself is made
up of approximately 15 exons and 544 amino acids. The
crystal structure of the CD45 intracellular domain, the
enzymatic protein phosphatase, has been solved (Nam
et al., 2005). However, the structure of the extracellular
domain is not yet known.
High-specificity commercially available antibodies exist
for distinguishing the hematopoietic cells from mice of a
CD45.1 or CD45.2 background; clone A20 specifically rec-
ognizes CD45.1, while clone 104 specifically recognizes
CD45.2. TheCD45 epitope that forms the basis of this spec-
ificity has not previously been defined.
An examination of the sequence differences between
CD45.1 and CD45.2 reveals numerous base changes
throughout the transcript (Zebedee et al., 1991). How-
ever, despite these changes, the CD45.1 and CD45.2 pro-
teins differ only by five amino acids in the extracellular
domain (Zebedee et al., 1991). Thus, we felt that one of
these amino acids, or a combination thereof, most likely
represents the epitope of the two monoclonal antibodies
that differentially recognize the CD45.1 and CD45.2
isoforms.
Using site-directedmutagenesis, we found that a single A
to G point mutation (base pair 904, AAA/GAA) resulting
in a lysine to glutamic acid (K302 / E302) amino acid
change, formed the entire basis of the CD45 antibody spec-
ificity. The glutamic acid alteration occurs in an exposed
loop of the first of three fibronectin type 3 domains found
in the extracellular domain of CD45. The homologous
arginine residue in the X-ray structure of the human fibro-
nectin type 3 protein is highlighted in the ribbon model
shown in Figure 2A.
The antibody specificity that results from this point
mutation was validated by transient transfection of these
variant CD45 open reading frames into 293T human
embryonic kidney (HEK) cells. Flow cytometry using the
commercially available anti-CD45.1 (A20) and anti-CD45.2 (104) antibodies confirmed the switch in antibody
recognition that resulted from the K302E amino acid
change (Figure 2B).
The C57BL/6N-CD45.1STEM Knockin Mouse Was
Generated with a Single Amino Acid Change
We designed and generated a mouse bearing the single
CD45 A904 /G904 point mutation in the background
of a C57BL/6N embryonic stem cell line (Figures 2C
and S1) using the contracted services of inGenius Target-
ing Laboratories (iTL). The mice were crossed with an Flp
recombinase mouse to remove the FRT/neomycin resis-
tance cassette (NeoR) and then bred to homozygosity
(Figure S2).
The CD45.1STEM Hematopoietic Stem Cells
Demonstrate Equivalence in Competitive
Transplantation Assays
Competitive bone marrow transplantation assays were
performed to compare the fitness of the conventional
CD45.1-expressing strain B6.SJL and ourCD45.1STEM strain
against CD45.2 C57BL/6J or C57BL/6NJ (Table 1 and Fig-
ure 3). The assays were performed using both WT C57BL/
6NJ and well as B6.SJL-PtprcaPepcb/Boy*C57BL/6NJ F1
hybrid recipients.
Donor mice were matched for age and gender. Donor
cells were pooled from three mice to minimize individual
variation, purified over a Ficoll density gradient, and
pooled at a 1:1 ratio. A total of 1 million cells (500,000 cells
from each genotype) were transplanted by tail vein injec-
tion into lethally irradiated mice, and the ratio of trans-
planted cells was confirmed by flow cytometry. Recipient
mice were conditionedwith two doses of 600 cGy radiation
(separated by 8–12 hr, last dose given 18–24 hr prior to
transplantation). This resulted in less than 5% residual
recipient marrow during the 4month post-transplantation
analysis.
WT B6.SJL HSPC showed a consistent and inherent
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Figure 2. A Single Amino Acid Change Deter-
mines the Specificity of CD45.1 and CD45.2
Antibodies
(A) A ribbon model of the extracellular fibro-
nectin type III domain. The K302E mutation is
highlighted.
(B) The single K302E amino acid change de-
termines CD45.1 versus CD45.2 antibody speci-
ficity of the Ptprc (CD45) gene. 293T human
embryonic kidney cells were transiently trans-
fected with a plasmid containing the original
CD45.2 open reading frame, or the open reading
frame with the K302E mutation, and then
stained with anti-CD45.1 (clone A20) or anti-
CD45.2 (clone 104) antibodies.
(C) Design of the CD45.1STEM mouse bearing a
single point mutation targeting the Ptprc gene
in the background of the C57BL/6N strain. The
long homology (red), middle homology (green),
and short homology (blue) arms are indicated.
See also Figure S1.mice (Figure 1B; n = 74), consistent with previous results
(Waterstrat et al., 2010). This effect remained apparent
when transplanting into F1 B6.SJL*C57BL/6J hybrids (Fig-
ure 3A; n = 31), arguing against an immunological cause
of rejection.
In comparison, HSPCs derived from CD45.1STEM
HSPCs were functionally equivalent to C57BL/6 HSPCs
in hematopoietic reconstitution at 16 weeks (Figure 3B;
n = 68). They were also functionally equivalent when
compared specifically with HSPCs from the C57BL/6NJ
strain (Figure 3C; n = 40), arguing against any subtle sub-
strain variation.
The disadvantage of the B6.SJL HSPC was most pro-
nounced in the myeloid (Figure 4A) and B-lymphoid (Fig-
ure 4B) lineages and less pronounced in the T-lymphoid
lineage (Figure 4C). Of note, there was a subtle but statisti-988 Stem Cell Reports j Vol. 6 j 985–992 j June 14, 2016cally significant advantage of the CD45.1STEM HSPCs in
reconstitution of the myeloid lineage at 16 weeks (Fig-
ure 4A, left panel, p = 0.018). However, since reconstitution
of the other lineages is equally balanced, and since there
was statistical equivalence in aggregate, we do not regard
this as reflecting a biologically meaningful difference, but
investigators should be aware of this possibility. Rather,
we think the result is due to our experimental design.
By design, we transplanted a small number of donor
cells (only 500,000 cells per strain) to stress the stem cell
compartment, and this resulted in increased mouse to
mouse variability (Figure S3A).
The functional equivalence of the C57BL/6N-
CD45.1STEM HSPCs with C57BL/6 strains was consistent
with our hypothesis that the single point mutant knockin
mouse would act as an improved competitor strain.
AB
C
Figure 3. The CD45.1STEM Mouse Is Functionally Equivalent to
C57BL/6 in Competitive Transplant Assays
For all competitive transplantation experiments, 500,000 nucle-
ated bone marrow cells from each pool of CD45.2 and CD45.1 donors
were co-transplanted into lethally irradiated recipients. The
percent reconstitution was tracked in the peripheral blood over a
period of 16 weeks.
(A) HSPCs derived from the current B6.SJL (CD45.1) competitor
strain have an inherent competitive disadvantage when compared
with HSPCs from wild-type C57BL/6 (CD45.2) mice even when
transplanted into the background of F1 B6.SJL*C57BL/6J hybridDISCUSSION
Our data demonstrate that, by introducing a single point
mutation into the genetic background of a C57BL/6N
mouse, we could generate a knockin strain that is iden-
tifiable using the commercially available CD45.1 anti-
body (clone A20). HSPCs from this knockin strain, named
C57BL/6N-CD45.1STEM (single targeted exon mutation)
are equivalent in competitive transplant assays when
compared with HSPCs from either C57BL/6N or C57BL/
6J mice.
This has important implications for competitive trans-
plantation experiments. Because they have the same recon-
stitution potential, modified HSPCs from any C57BL/6N
or C57BL/6J strain can be directed compared with our
CD45.1STEM strain without an additional control group.
This contrasts with the situation when using the current
B6.SJL competitor strain. Given the inherent disadvantage
of WT B6.SJL HSPCs, one requires both a test competitive
transplant (CD45.2 test versus B6.SJL) as well as a control
competitive transplant (CD45.2WT versus B6.SJL) in order
to correctly determine HSPC fitness. As such, the C57BL/
6N-CD45.1STEM strain provides a better competitor and of-
fers the possibility of reducing the number ofmice and cost
associated with competitive HSPC transplantation assays.
We identified the CD45 epitope that is recognized by
the anti-CD45.1 and anti-CD45.2 antibodies. Then, by
engineering a mouse strain with a single point mutation,
resulting in this single amino acid change in a C57BL/6N
background, we avoided alterations in introns or other reg-
ulatory domains and created a strain that allows for a truly
equivalent competitive bone marrow transplant.
We would like to highlight a few important methodolog-
ical variables in performing competitive HSPC transplanta-
tion assays. (1) We stress the importance of pooling bone
marrow cells from aminimumof three donormice. Despiterecipients. Three experiments, two in competition with wild-type
C57BL/6J donors and one in competition with wild-type C57BL/6NJ
donors, were performed (31 recipient mice in total).
(B) HSPCs derived from the CD45.1STEM competitor strain show
functional equivalence when compared with HSPCs from wild-type
C57BL/6 mice. Four experiments, two in competition with wild-
type C57BL/6J donors and two in competition with wild-type
C57BL/6NJ donors, were performed. The recipients in these four
experiments were a mixture of C57BL/6J, C57BL/6NJ, and F1
B6.SJL*C57BL/6J hybrids (68 recipient mice in total).
(C) HSPCs derived from the CD45.1STEM competitor strain show
functional equivalence when compared specifically with HSPCs from
the wild-type C57BL/6NJ substrain of mice. Two experiments were
performed (40 recipient mice in total). The results represent the
mean ± SEM Given the large number of replicates, the error bars are
not visible as they are smaller than the squares.
*p < 0.05, ***p < 0.001. See also Figure S3.
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Figure 4. The CD45.1STEM Strain Shows
Improved Reconstitution across Hemato-
poietic Lineages
(A–C) Assessment of hematopoietic recon-
stitution within myeloid (A), B-lymphoid
(B), or T-lymphoid (C) lineages for mice
transplanted with B6.SJL (left panels) or
CD45STEM (right panels) donor cells in
competition with wild-type C57BL/6 HSPCs.
Four experiments, two in competition with
wild-type C57BL/6J donors and two in
competition with wild-type C57BL/6NJ do-
nors, were performed. The results represent
the mean ± SEM. Given the large number of
replicates (left panels, n = 74; right panels,
n = 68), the error bars are not visible as they
are smaller than the squares. *p < 0.05,
**p < 0.01, and ***p < 0.001.the fact that these mice may be genetically identical WT
littermates, there exist subtle variations in reconstitution
ability between individuals that can beminimized by pool-
ingmultiple donors. (2) Slight differences in reconstitution
ability are exacerbated by transplanting low numbers of
HSPCs (Lacombe et al., 2010). As we transplanted only
500,000 bone marrow cells from each strain, this led to
impressive mouse to mouse variability that was overcome
by performing multiple biological replicates (Figure S3A).
(3) The high fractionated dose of radiation (2 3 600 cGy)
given as pre-transplant conditioning ensures that there
are few residual endogenous recipient cells, although
in all cases we would advocate the use of F1 hybrid
CD45.1*CD45.2 recipients to permit distinguishing the
doubly labeled residual host cells (Figure S3B).
In summary, the C57BL/6N-CD45.1STEM mouse repre-
sents a technical advance for investigators who wish to990 Stem Cell Reports j Vol. 6 j 985–992 j June 14, 2016accurately quantify the fitness of genetically, or otherwise
modified, HSPCs derived in the common background of
the C57BL/6N or C57BL/6J mouse strains. Unlike the
previous competitor strain, HSPCs from the CD45.1STEM
mouse have comparable reconstitution potential, elimi-
nating the need for a separate control group. For these rea-
sons, we propose that the CD57Bl/6N-CD45.1STEM mouse
should become the standard competitor in competitive
bone marrow transplantation assays.EXPERIMENTAL PROCEDURES
Site-Directed Mutagenesis
The mouse Ptprc cDNA was purchased from Genecopeia in a
Gateway-technology-compatible vector (cloneMOC23994). Using
the QuickChange II kit (Agilent Technologies), PCR reactions were
designed to introduce the A904G mutation into the plasmid.
Following bacterial transformation, individual colonies were
screened by Sanger sequencing. The desired mutants were recom-
bined using LR clonase II (Thermo Fisher) into the pLEX_307 len-
tiviral expression vector, where expression is driven by the eIF1a
promoter (a kind gift from the Broad Institute, Cambridge, MA).
Screening of Mutations for Antigenicity
HEK293T cells were transfected (FuGENE, Promega) with
pLEX_307 plasmids driving expression of the native or mutant
mouse Ptprc protein described above. Four days following trans-
fection, cells were trypsinized and the single-cell suspension was
incubated with fluorochrome-conjugated antibodies CD45.1-
FITC (A20) and CD45.2-APC (104) (eBioscience). The cells were
analyzed on an LSR II instrument (BD Biosciences).
Design of the Targeting Vector
An 8.70 kb region used to construct the targeting vector was first
subcloned from a positively identified C57BL/6 bacterial artificial
clone (BAC; RP23:131J7). The region was designed such that the
long homology arm (LA) extends 6.19 kb 50 to the site of the
point mutation (A/G) in exon 7 and the FRT flanked NeoR
cassette was inserted 400 bp 30 to the point mutation. The short
homology arm (SA) extends 2.11 kb 30 to the FRT flanked NeoR
cassette. The targeting vector was constructed using Red/ETrecom-
bineering technology.
The BAC was subcloned into a 2.4 kb backbone vector (pSP72;
Promega) containing an ampicillin selection cassette for retrans-
formation of the construct prior to electroporation. A pGK-gb2
FRT NeoR cassette was inserted into the gene as described in
the project schematic. The total size of the targeting construct
(including the vector backbone and NeoR cassette) was 14.25 kb.
The mutation was engineered by overlap extension PCR. Two
primary PCR fragments that overlap 12 bp just 50 to the point mu-
tation were generated using primers PT1/PT2 and PT3/PT4. The
A/Gmutationwas engineered into primer PT3. The two primary
products were then mixed and used as a template in a secondary
PCR reaction inwhich the PT1/PT4 primer pair amplifies the entire
sequence containing the point mutation. A 50 endogenous restric-
tion enzyme site, PmlI, was used with the 30 endogenous restric-
tion enzyme site, PacI, for insertion of the mutant PCR fragment
into the subcloned vector (Figure S1).
The targeting vector was confirmed by restriction analysis after
each modification step and by sequencing using primers designed
to read from the selection cassette into the SA (N1) and the
genomic sequence containing the point mutations (N2). P6 and
T73 primers anneal to the BAC subclone sequence and read into
the 50 and 30 ends of the subcloned vector. Sequencing with
primers PROC PT2 confirmed that no errors were introduced into
the PCR modified region.
Generation of Knockin Mice
The linearized targeting plasmid DNAwas electroporated into em-
bryonic stem cells. After selecting with G418, resistant colonies
were screened for homologous recombination of the Ptprc tar-
geted allele by PCR and Southern blot analysis. The clones with
homologous recombination were identified and isolated. These
embryonic stem cells were injected into blastocysts from BALB/cmice. The blastocysts were transferred to pseudopregnant ICR
foster mothers, and chimeric males were obtained. Subsequently,
chimeric mice were mated to mice constitutively expressing the
Flp recombinase to produce F1 heterozygous, targeted, NeoR
cassette-deleted mice. The F1 mice were crossed to produce F2
homozygous mutants (CD45.1STEM) and WT littermate controls.
To screen for deletion of the NeoR cassette, primer set NDEL1
and NDEL2 were used. The PCR reaction consisted of 30 cycles
(denature at 94 for 30 s, anneal at 60 for 30 s, extension at 72
for 60 s). The PCR product of the WT reaction is 295 bp. After
neomycin deletion, one set of FRT sites remain (70 bp). A second
band with a size of 365 confirmed deletion of the NeoR cassette.
The intact NeoR cassette is not amplified by this PCR reaction
because of its large size (Figure S2A).
Genotyping Mice for the CD45.1STEM Point Mutation
Genotype confirmation to identify the A904G point mutation was
done by sequencing the PCR product amplified by primers SC1
(upstream) and REVG1 (downstream). The PCR reaction consisted
of 30 cycles (denature at 94 for 30 s, anneal at 55 for 30 s, exten-
sion at 72 for 60 s). The amplified product of the SC1/REVG1 re-
action is 678 bp, and the SC1 primer can be used in the subsequent
sequencing reaction (Figure S2B).
Competitive Transplantation Assays
All experiments were performed in accordance with the institu-
tional animal care and use committee guidelines at Massachusetts
General Hospital.
Transplantation experiments were performed using 8- to
12-week-old, age-matched female mice. Total bone marrow nucle-
ated cells were extracted from the long bones of C57BL/6NJ
mice (Jackson Laboratory), B6.SJL-PtprcaPepcb/BoyJ (Jackson
Laboratory), and CD45.1STEM, then purified using Ficoll-Paque
Plus (GE Healthcare). For each experiment, the bone marrow was
extracted from three donor mice per group and then pooled prior
to transplantation.
Twenty-four hours prior to transplantation, recipient mice were
lethally irradiated with two 600 cGy doses separated by 6 hr. For
each recipient, a total of one million nucleated bone marrow cells
were injected in the tail vein: 500,000 cells from a C57BL/6 donor
group mixed with 500,000 cells of either B6.SJL-PtprcaPepcb/BoyJ
or CD45.1STEM donor group.
Peripheral blood was sampled every 4 weeks, and the red blood
cells were lysed with ACK buffer (Lonza). The leukocytes were
resuspended in PBS supplemented with 2% fetal bovine serum
and EDTA (1 mM). The cells were labeled (30 min, 4) with the
following antibodies: CD3-BUV395, CD45.1-FITC, B220-PE,
CD11b-PE-Cy7, CD45.2-APC. The cells were analyzed on an LSRII
instrument (BD Biosciences).
Statistical Analysis of the Competitive Transplants
Following transplantation of the 1:1 mixture of CD45.1+ and
CD45.2+ cells, the ratio of CD45.1 cells to CD45.2 cells was as-
sessed by flow cytometry to account for slight imbalances in mix-
ing. This ‘‘time 0 real ratio’’ was used to adjust the subsequent ratios
of CD45.1 and CD45.2 cells in the peripheral blood at weeks 4, 8,
12, and 16. In this manner, the data can be presented to mostStem Cell Reports j Vol. 6 j 985–992 j June 14, 2016 991
clearly demonstrate the deviation, or lack of deviation, from the
starting point of 50%.
At each time point, we analyzed the difference between CD45.1
reconstitution and CD45.2 reconstitution. This was done via the
Wilcoxon signed-rank test which was used to compare CD45.1
and CD45.2 reconstitution and obtain raw p values; then, in order
to adjust for multiple testing, the Benjamini-Hochberg procedure
was used to get adjusted p values.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.2016.
04.010.
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